Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease

Steven L Barriere; David J Farrell; Paul R Rhomberg; Ronald N Jones

doi:10.1016/j.diagmicrobio.2014.09.002

Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease

Diagn Microbiol Infect Dis. 2014 Dec;80(4):327-9. doi: 10.1016/j.diagmicrobio.2014.09.002. Epub 2014 Sep 6.

Authors

Steven L Barriere¹, David J Farrell², Paul R Rhomberg², Ronald N Jones²

Affiliations

¹ Theravance Biopharma US, Inc., 901 Gateway Boulevard, South San Francisco, CA 94080, USA. Electronic address: SBarriere@theravance.com.
² JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA.

PMID: 25306423
DOI: 10.1016/j.diagmicrobio.2014.09.002

Abstract

Telavancin biological activity, determined by serum titers against a reference strain of Staphylococcus aureus, was maintained in the serum of subjects with severe renal impairment or end-stage renal disease suggesting that there is no apparent effect of renal function on in vitro activity of telavancin.

Keywords: Renal impairment; Staphylococcus aureus; Telavancin.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aminoglycosides / blood
Aminoglycosides / pharmacokinetics
Aminoglycosides / pharmacology*
Anti-Bacterial Agents / blood
Anti-Bacterial Agents / pharmacokinetics
Anti-Bacterial Agents / pharmacology*
Female
Humans
Kidney Failure, Chronic / drug therapy*
Kidney Failure, Chronic / physiopathology
Lipoglycopeptides
Male
Microbial Sensitivity Tests
Middle Aged
Reference Values
Renal Insufficiency / drug therapy*
Renal Insufficiency / physiopathology
Staphylococcal Infections / drug therapy
Staphylococcus aureus / drug effects*
Staphylococcus aureus / pathogenicity

Substances

Aminoglycosides
Anti-Bacterial Agents
Lipoglycopeptides
telavancin